Winning Lawsuits, Raising New Capital, He Wants to Make Million-Dollar 'Cancer Fighting Shots' Affordable 赢官司、融新钱，他想把百万「抗癌针」变平价

TL;DR

• Shenzhen Bay Island Cell completed a 140 million RMB Series A funding round led by Songhe Capital to advance its non-gene-editing universal CAR-T platform.
• Founder Fan Xiaohu won a high-profile trade secret lawsuit against Legend Biotech, clearing legal hurdles for his new venture's independent development.
• The company utilizes a proprietary protein degradation technology to remove TCR-CD3 complexes from donor T-cells, avoiding the safety and cost issues associated with traditional gene editing.
• Early clinical data presented at ASCO shows promising efficacy and safety in diffuse large B-cell lymphoma patients, with one patient maintaining complete remission for 14 months.
• The strategic goal is to produce "off-the-shelf" CAR-T therapies that are standardized, low-cost, and scalable, potentially allowing outpatient administration rather than complex hospital-based customization.

Why It Matters

This development highlights a critical pivot in the cell therapy industry away from expensive, customized autologous treatments toward scalable, universal solutions that can democratize access to life-saving cancer therapies. For investors and biotech professionals, it demonstrates that non-consensus technical routes, such as protein degradation over gene editing, can yield viable clinical candidates and attract significant capital despite market trends favoring other modalities like in vivo CAR-T.

Technical Details

• Platform Technology: Revo-U, a non-gene-editing universal CAR-T platform that uses antibody-mediated targeted protein degradation to eliminate the TCR-CD3 complex, preventing host-versus-graft reactions without altering the genome.
• Manufacturing Advantages: The process avoids physical stressors like electroporation, resulting in healthier T-cells with higher functional integrity; aims for batch capacities of 3,000 doses to significantly reduce production costs compared to current standards.
• Clinical Data: Presented four early-stage human cases at ASCO for CD19 CAR-T in diffuse large B-cell lymphoma; notable outcomes include sustained complete remission in a low-dose patient for ~14 months and high T-cell expansion peaks (>19 million copies/mL) in a high-dose patient.
• Safety Profile: Observed manageable side effects, including Grade 1 cytokine release syndrome (CRS) lasting five days in one case, while aiming to optimize conditioning regimens to further improve the safety-to-efficacy balance.
• Pipeline Strategy: Focuses initially on hematological malignancies to validate the platform, with future expansions into solid tumors and autoimmune diseases, leveraging both drug registration and medical technology transfer pathways.

Industry Insight

The success of this non-gene-editing approach suggests that the industry's heavy reliance on CRISPR or viral gene editing for universal CAR-T may not be the only viable path, offering an alternative that could bypass regulatory and safety bottlenecks associated with genomic modifications. Investors should look beyond current hype cycles (such as the rush into in vivo CAR-T) and evaluate companies with differentiated, scientifically robust platforms that address the fundamental economic barriers of cell therapy scalability. Finally, the resolution of the legal dispute underscores the importance of IP clarity and founder independence in the CGT sector, where talent mobility and intellectual property ownership remain high-stakes factors for venture viability.